A Phase 4 interventional study of Blood Stopper (Ankaferd) in Epistaxis Nosebleed, sponsored by Ankara Ataturk Sanatorium Training and Research Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-08.
Sponsored by Ankara Ataturk Sanatorium Training and Research Hospital · Phase 4, Interventional, and Treatment
In this randonmized controlled trial, aim to compare the effectiveness of local administration of tranexamic acid and blood stopper (Ankaferd®) on cessation of bleeding in epistaxis patients.
Anterior tamponade is frequently used in the management of anterior epistaxis. However, this procedure is often uncomfortable for patients. Therefore, instead of this physical tampon, various pharmacologic agents such as tranexamic acid, blood stoppers (ankaferd®), and adrenaline can be used in epistaxis management. Although the superiority of various agents used in the management of anterior epistaxis has been evaluated in published network meta-analyses, these meta-analyses do not compare ankaferd and Tranexamic acid since there are no studies with each other. In order to close the gap in the existing literature, this study aims to evaluate the superiority of local administration of tranexamic acid and ankaferd® in terms of cessation of bleeding in patients with anterior epistaxis.
96 studies on the registry are indexed under Epistaxis; 22 are open to participants now.
This study's planned enrollment of 186 is above the median of 64 across 81 interventional studies indexed under Epistaxis.
Browse Epistaxis studies →Ankara Ataturk Sanatorium Training and Research Hospital is the lead sponsor of 38 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients will be asked to clean their nose with tap water as part of the routine treatment before the administration. After then, Tranexamic acid (500mg/5 ml) will be sprayed through the bleeding side nostril and then external pressure will be applied to the nose for 10 minutes.
Drug: Blood Stopper (Ankaferd)
Patients will be asked to clean their noses with tap water as part of the routine treatment before the administration. After then, 5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
Drug: Blood Stopper (Ankaferd)
5 ml of Ankaferd® will be sprayed through the bleeding side nostril and external nasal pressure will be performed for 10 minutes.
Cessation of bleeding
Primary outcome was definition cessation in bleeding at 10-minutes after performing local drug interventions.
Time frame: 10-minutes after performing local drug interventions.
Re-bleeding
The secondary outcome was a comparison of the re-bleeding rate within 24 hours in the two treatments groups.
Time frame: From cessation of bleeding to re-bleeding within 24-hours.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara Ataturk Sanatorium Training and Research Hospital